Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
Last trade$0.1006
Day change-$0.0354 (-26.03%)
Day range$0.0961 – $0.14
Volume525,883
Market cap$5M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$5.38M
Price / earnings
—
Price / book
-1.58×
Price / sales
97.89×
EV / sales
52.98×
EV / EBITDA
-0.05×
Profitability
Earnings per share
-$1.29
Return on assets
-149.72%
Return on equity
1,457.34%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-1.17×
Current ratio
0.83×
Quick ratio
0.83×
Cash ratio
0.41×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$38.05M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SNTI, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$17K
$16K
$22K
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$17K
$16K
$22K
$0
$0
$0
$0
$0
Selling, general and administrative
$6.74M
$6.23M
$5.85M
$6.43M
$6.77M
$7.12M
$8.08M
$6.56M
Research and development
$7.77M
$5.28M
$7.76M
$10.52M
$10.03M
$9.28M
$7.77M
$8.66M
Total operating expenses
$14.51M
$4.63M
$18.66M
$16.95M
$16.8M
$16.4M
$16.17M
$15.22M
Operating income
-$14.49M
-$4.62M
-$18.64M
-$16.95M
-$16.8M
-$16.4M
-$16.17M
-$15.22M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$12.75M
-$4.22M
-$14.47M
-$18.13M
-$14.73M
-$14.11M
-$610K
-$28.87M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$12.75M
-$4.22M
-$14.47M
-$18.13M
-$14.73M
-$14.11M
-$610K
-$28.87M
Net income attributable to common shareholders
-$12.75M
-$4.22M
-$14.47M
-$18.13M
-$14.73M
-$14.11M
-$3.13M
-$28.87M
EBITDA
-$13.82M
-$10.81M
-$12.69M
-$16.04M
-$15.88M
-$15.47M
-$14.92M
-$14.27M
Basic earnings per share
-$0.41
-$0.14
-$0.52
-$0.69
-$0.56
-$1.41
-$0.67
-$6.31
Diluted earnings per share
-$0.41
-$0.14
-$0.52
-$0.69
-$0.56
-$1.41
-$0.67
-$6.31
Recent news
Company coverage with links to the original publishers.
Over 100 pharmaceutical companies are actively developing 150+ pipeline drugs for Acute Myeloid Leukemia (AML), with approximately 10 drugs in late-stage development and 50+ in mid and early stages, focusing on targeted therapies and personalized treatment approaches.
Amerant Bancorp Inc. (AMTB) reported Q1 2025 earnings that missed consensus estimates, causing its stock price to drop 13.09%. Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by the company and its officers/directors.
Senti Biosciences, Inc. (SNTI) has stopped enrollment in a clinical trial for its solid tumor pipeline product SN301A due to observed dose-limiting toxicities, causing a 27.2% drop in the company's stock price.
Senti Biosciences, a clinical-stage biotechnology company, announced that it will present positive preliminary clinical results of its lead program SENTI-202 in the treatment of patients with Relapsed/Refractory AML on May 8, 2025.
The NK cell therapy market is experiencing significant growth, driven by rising interest in immuno-oncology and advancements in cell engineering technologies. Key players are investing in innovative approaches, including combination therapies and gene-modified NK cells, to improve clinical outcomes.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.